Hyperplasia of prolactin pituitary cells with or with out microadenoma

Chapters in this book

1. Frontmatter I
2. Preface V
3. Contents VII
4. I. Morphology
5. Structure and ultrastructure of prolactinomas 3
6. Prolactinomas and mixed adenomas with prolactin cells: an immunohistochemical study of the subcellular localization of hormones 15
7. Immunocytochemical, chemical and nuclear-DNA studies of pituitary tumours 27
8. Hyperplasia of prolactin pituitary cells with or with out microadenoma 35
9. Hormone-secretion in cell culture of microprolacti nomas, periadenomatous tissue and capsules 39
10. Immunocytochemical, ultrastructural and culture characteristics of prolactin-secreting pituitary adenomas 45
11. Immunohìstochemical hormone determinations in pituitary adenomas in comparison with endocrinological findings in vivo 57
12. New immunocytochemical observations in prolactinomas 69
13. Problematic divergencies between clinical and immunocytochemical findings in prolactinomas 73
14. Necrosis of prolactinoma cells after bromocriptine treatment 79
15. Spontaneous pituitary lesions and plasma prolactin levels in rats 85
16. II. Radiology
17. CT-findings in pituitary adenomas 91
18. Comparative study of normal subjects and cases with microadenoma on high-resolution computed tomography 105
19. III. Endocrinological and clinical aspects
20. Actions of dopamine receptor agonists at the pituitary level 115
21. Dopamine and prolactinomas 123
22. Rhythmometric study of the circadian profile of plasma prolactin in patients with prolactinoma or empty sella syndrome 131
23. Prolactin responses to thyrotropin-releasing hormone, metoclopramide and insulin-induced hypoglycaemia in hyperprolactinaemic and normoprolactinaemic patients 141
24. Evidence for functional impairment of growth hormone secretion in prolactinoma 147
25. TSH response to dopamine receptor blockade in women with PRL-secreting microadenoma: Long effect of surgical removal 155
26. Prolactin and TSH responses to TRH and domperidone in delayed puberty 161
27. Anterior pituitary function in patients with prolactinomas 165
28. Pituitary adenomas with hyperprolactinaemia in males 169
29. Prolactinoma in multiple endocrine neoplasia type I 179
30. Recurrence of hyperprolactinaemia detected in long-term follow-up of surgically normalized microprolactinomas 183
31. Impairment of pituitary hormone secretion in patients with prolactinoma 189
32. IV. Surgical treatment
33. The recurrence of pituitary adenoma — a management challenge 199
34. Transsphenoidal operations for prolactinomas 209
35. Prolactinomas: surgical results in 96 cases 225
36. Effect of transsphenoidal surgery on pituitary function 231
37. Transsphenoidal microsurgical treatment of 77 prolactinomas 235
38. Review of 56 prolactin-secreting pituitary adenomas 247
39. The effect of transsphenoidal selective microadenomectomy on patients with prolactinomas 253
40. Surgical results and long-term follow-up in female and male prolactinomas 261
41. Otoliquorrhoea in large prolactinomas. Pathomechanism and surgical management 275
42. Invasive prolactinomas in adolescents 281
43. Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas 289
44. Long-term follow-up of prolactinomas. Clinical and morphologic correlation 295
45. Clinicopathologîcal and neurosurgical comparative analysis of operated recurrent prolactinomas and non-secreting chromophobe pituitary adenomas 301
46. V. Pharmacotherapy
47. New aspects of medical treatment of prolactinomas 309
48. Conservative management of prolactinoma 319
49. Effect of bromocriptine therapy on large prolactinomas 327
50. Macroprolactinomas in male patients: efficiency of treatment with a new dopaminergic drug (CU 32-085-Sandoz), tumour calcification and relative significance of preoperative tumour volume regression as estimated by CT-scan 337
51. Evidence for spontaneous tumour shrinkage in a 45-year-old patient with a 20-year history of untreated microprolactinoma 347
52. The influence of various forms of treatment on serum levels of prolactin, growth hormone and insulin-like growth factors I and II in patients with hyperprolactinaemia and acromegaly 353
53. Persisting partial suppression of growth hormone excess in acromegaly after long term treatment with bromocriptine 361
54. Medical and surgical treatment of micro and macroprolactinomas: seven years follow-up of 65 cases 365
55. VI. Aspects of gynecology and obstetrics
56. Management of prolactinomas in pregnancy 373
57. Long-term follow-up of hyperprolactinaemia in women 387
58. Prophylactic bromocriptine treatment during pregnancy of women with macroprolactinomas: report of thirteen pregnancies 397
59. Natural regression after pregnancy of a CT visualized microprolactinoma 405
60. Prolactin levels and ovarian function after surgical treatment of prolactinomas 411
61. Pregnancies after treatment of prolactinomas: course and complications 417
62. Psychosomatic findings in patients with elevated prolactin 425
63. List of contributors 431
64. Authors' index 433
65. Subject index 436